肿瘤细胞治疗研究
英文原题：Evolving immunotherapeutic solutions for triple-negative breast carcinoma.
三阴性乳腺癌（TNBC）因其高度侵袭性和治疗选择有限，仍然是一个严峻的临床难题。
三阴性乳腺癌（TNBC）因其高度侵袭性和治疗选择匮乏，仍然是临床上的重大难题。然而，免疫治疗策略的不断发展为攻克这一难题开辟了有前景的途径。本综述讨论了TNBC免疫治疗的进展，强调因肿瘤微环境（TME）多样性而需要个性化干预。免疫检查点抑制剂（ICIs）具有关键意义，无论是作为单药治疗还是与细胞毒性药物联合使用。此外，同时抑制多个免疫检查点代表了一种增强癌症免疫治疗疗效的有效方法。当ICIs与PARP抑制剂、抗血管生成药物和ADC（抗体药物偶联物）等靶向治疗联合使用时，已观察到协同效应。新兴策略包括肿瘤疫苗、细胞免疫治疗和溶瘤病毒，利用免疫系统选择性破坏恶性细胞的能力。本综述深入考察了TNBC免疫治疗发展的多元格局，对该领域各种进展提供了细致的见解。此外，免疫治疗干预为TNBC带来了希望，但仍需进一步研究以优化。
Triple-negative breast carcinoma (TNBC) remains a formidable clinical hurdle owing to its high aggressiveness and scant therapeutic options. Nonetheless, the evolving landscape of immunotherapeutic strategies opens up promising avenues for tackling this hurdle. This review discusses the advancing immunotherapy for TNBC, accentuating personalized interventions due to tumor microenvironment (TME) diversity. Immune checkpoint inhibitors (ICIs) hold pivotal significance, both as single-agent therapies and when administered alongside cytotoxic agents. Moreover, the concurrent inhibition of multiple immune checkpoints represents a potent approach to augment the efficacy of cancer immunotherapy. Synergistic effects have been observed when ICIs are combined with targeted treatments like PARP inhibitors, anti-angiogenics, and ADCs (antibody-drug conjugates). Emerging tactics include tumor vaccines, cellular immunotherapy, and oncolytic viruses, leveraging the immune system's ability for selective malignant cell destruction. This review offers an in-depth examination of the diverse landscape of immunotherapy development for TNBC, furnishing meticulous insights into various advancements within this field. In addition, immunotherapeutic interventions offer hope for TNBC, needing further research for optimization.
MEMBER ACCOUNT
登录成功会直接打开下一页。
